Harrow Health, Inc. (HROW)
USD 23.97
(2.11%)
USD 23.97
(2.11%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 89.97 Million USD | 46.79% |
| 2022 | 61.29 Million USD | 16.97% |
| 2021 | 52.39 Million USD | 55.67% |
| 2020 | 33.66 Million USD | -4.32% |
| 2019 | 35.17 Million USD | 17.0% |
| 2018 | 30.06 Million USD | 18.23% |
| 2017 | 25.43 Million USD | -1.0% |
| 2016 | 25.69 Million USD | 32.89% |
| 2015 | 19.33 Million USD | 80.43% |
| 2014 | 10.71 Million USD | 39.2% |
| 2013 | 7.69 Million USD | 79.88% |
| 2012 | 4.27 Million USD | 355.57% |
| 2011 | 939.22 Thousand USD | -62.47% |
| 2010 | 2.5 Million USD | -45.17% |
| 2009 | 4.56 Million USD | 21.83% |
| 2008 | 3.74 Million USD | 31.02% |
| 2007 | 2.85 Million USD | 6088.35% |
| 2006 | 46.2 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 34.87 Million USD | 12.62% |
| 2024 Q1 | 30.96 Million USD | 4.79% |
| 2023 Q2 | 21.11 Million USD | 27.05% |
| 2023 Q1 | 16.62 Million USD | 4.27% |
| 2023 Q3 | 22.45 Million USD | 6.33% |
| 2023 FY | 89.97 Million USD | 46.79% |
| 2023 Q4 | 29.54 Million USD | 31.59% |
| 2022 Q1 | 14.05 Million USD | -15.4% |
| 2022 FY | 61.29 Million USD | 16.97% |
| 2022 Q4 | 15.94 Million USD | -1.57% |
| 2022 Q3 | 16.19 Million USD | 7.27% |
| 2022 Q2 | 15.09 Million USD | 7.42% |
| 2021 Q3 | 17.48 Million USD | 83.09% |
| 2021 FY | 52.39 Million USD | 55.67% |
| 2021 Q1 | 8.75 Million USD | 9.01% |
| 2021 Q2 | 9.54 Million USD | 9.05% |
| 2021 Q4 | 16.61 Million USD | -4.96% |
| 2020 Q1 | 8.81 Million USD | 8.6% |
| 2020 Q3 | 9.1 Million USD | 18.21% |
| 2020 FY | 33.66 Million USD | -4.32% |
| 2020 Q2 | 7.7 Million USD | -12.65% |
| 2020 Q4 | 8.03 Million USD | -11.79% |
| 2019 FY | 35.17 Million USD | 17.0% |
| 2019 Q1 | 8.94 Million USD | -5.26% |
| 2019 Q2 | 9.05 Million USD | 1.23% |
| 2019 Q3 | 9.05 Million USD | -0.07% |
| 2019 Q4 | 8.12 Million USD | -10.29% |
| 2018 Q2 | 6.85 Million USD | 4.2% |
| 2018 Q3 | 7.19 Million USD | 5.05% |
| 2018 Q4 | 9.44 Million USD | 31.24% |
| 2018 Q1 | 6.57 Million USD | 9.02% |
| 2018 FY | 30.06 Million USD | 18.23% |
| 2017 Q4 | 6.03 Million USD | 3.2% |
| 2017 Q3 | 5.84 Million USD | -11.27% |
| 2017 Q2 | 6.58 Million USD | -5.52% |
| 2017 FY | 25.43 Million USD | -1.0% |
| 2017 Q1 | 6.97 Million USD | 11.89% |
| 2016 Q4 | 6.23 Million USD | -8.8% |
| 2016 Q2 | 6.74 Million USD | 14.56% |
| 2016 Q3 | 6.83 Million USD | 1.31% |
| 2016 FY | 25.69 Million USD | 32.89% |
| 2016 Q1 | 5.88 Million USD | -5.84% |
| 2015 Q3 | 5.01 Million USD | 13.92% |
| 2015 Q4 | 6.25 Million USD | 24.77% |
| 2015 FY | 19.33 Million USD | 80.43% |
| 2015 Q1 | 3.67 Million USD | 25.67% |
| 2015 Q2 | 4.39 Million USD | 19.74% |
| 2014 Q2 | 2.79 Million USD | 19.56% |
| 2014 FY | 10.71 Million USD | 39.2% |
| 2014 Q4 | 2.92 Million USD | 9.86% |
| 2014 Q3 | 2.66 Million USD | -4.78% |
| 2014 Q1 | 2.33 Million USD | 23.26% |
| 2013 Q4 | 1.89 Million USD | -9.39% |
| 2013 FY | 7.69 Million USD | 79.88% |
| 2013 Q1 | 1.47 Million USD | 1.13% |
| 2013 Q2 | 2.23 Million USD | 51.42% |
| 2013 Q3 | 2.09 Million USD | -6.32% |
| 2012 Q3 | 1.25 Million USD | 11.78% |
| 2012 Q2 | 1.11 Million USD | 147.45% |
| 2012 FY | 4.27 Million USD | 355.57% |
| 2012 Q1 | 451.91 Thousand USD | 44.32% |
| 2012 Q4 | 1.45 Million USD | 16.69% |
| 2011 Q2 | 145.76 Thousand USD | -64.78% |
| 2011 Q1 | 413.82 Thousand USD | 1.61% |
| 2011 Q3 | 66.49 Thousand USD | -54.38% |
| 2011 Q4 | 313.14 Thousand USD | 370.92% |
| 2011 FY | 939.22 Thousand USD | -62.47% |
| 2010 FY | 2.5 Million USD | -45.17% |
| 2010 Q3 | 727.77 Thousand USD | 46.5% |
| 2010 Q2 | 496.76 Thousand USD | -42.95% |
| 2010 Q1 | 870.74 Thousand USD | 12.13% |
| 2010 Q4 | 407.28 Thousand USD | -44.04% |
| 2009 FY | 4.56 Million USD | 21.83% |
| 2009 Q1 | 1.62 Million USD | 68.82% |
| 2009 Q4 | 776.52 Thousand USD | -16.43% |
| 2009 Q3 | 929.23 Thousand USD | -24.47% |
| 2009 Q2 | 1.23 Million USD | -24.43% |
| 2008 Q4 | 964.35 Thousand USD | 215.54% |
| 2008 Q1 | 666.95 Thousand USD | -57.08% |
| 2008 FY | 3.74 Million USD | 31.02% |
| 2008 Q3 | -834.67 Thousand USD | -165.19% |
| 2008 Q2 | 1.28 Million USD | 91.98% |
| 2007 FY | 2.85 Million USD | 6088.35% |
| 2007 Q2 | 1109.00 USD | -41.54% |
| 2007 Q3 | -969.14 Thousand USD | -87489.0% |
| 2007 Q4 | 1.55 Million USD | 260.33% |
| 2007 Q1 | 1897.00 USD | -34.65% |
| 2006 Q4 | 2903.00 USD | -62.46% |
| 2006 FY | 46.2 Thousand USD | 0.0% |
| 2006 Q3 | 7733.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -990.202% |
| Alpha Teknova, Inc. | 45.85 Million USD | -96.195% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 54.091% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -100.591% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 43.487% |
| Cosmos Health Inc. | 26.18 Million USD | -243.66% |
| Journey Medical Corporation | 54.59 Million USD | -64.804% |
| Embecta Corp. | 528.4 Million USD | 82.973% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 66.909% |
| Dynavax Technologies Corporation | 219.14 Million USD | 58.944% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 84.75% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 72.433% |
| PainReform Ltd. | 9.58 Million USD | -838.783% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -585.536% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -585.536% |
| SCYNEXIS, Inc. | 51.84 Million USD | -73.532% |
| Safety Shot Inc | 12.1 Million USD | -642.983% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -2831.492% |
| Procaps Group, S.A. | 199.47 Million USD | 54.896% |
| Theratechnologies Inc. | 72.75 Million USD | -23.664% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -852.498% |
| Biofrontera Inc. | 39.95 Million USD | -125.163% |
| DURECT Corporation | 43.71 Million USD | -105.817% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 82.992% |
| Cronos Group Inc. | 96.7 Million USD | 6.965% |
| OptiNose, Inc. | 85.1 Million USD | -5.724% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 61.239% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -129.798% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 1041.042% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 71.358% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -824.618% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -109.042% |
| Radius Health, Inc. | 265.92 Million USD | 66.167% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -550.004% |
| ProPhase Labs, Inc. | 37.85 Million USD | -137.697% |
| Phibro Animal Health Corporation | 260.29 Million USD | 65.435% |
| Procaps Group S.A. | 187.24 Million USD | 51.949% |
| Alvotech | 285.43 Million USD | 68.479% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -815.756% |
| Viatris Inc. | 5.96 Billion USD | 98.492% |
| Rockwell Medical, Inc. | 15.37 Million USD | -485.228% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -50.356% |
| SIGA Technologies, Inc. | 22.04 Million USD | -308.17% |
| Tilray Brands, Inc. | 251.35 Million USD | 64.205% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -83.476% |
| Shineco, Inc. | 17.94 Million USD | -401.297% |
| PetIQ, Inc. | 192.72 Million USD | 53.315% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -2154.319% |
| Incannex Healthcare Limited | 30.05 Million USD | -199.381% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 94.364% |
| Alimera Sciences, Inc. | 62.64 Million USD | -43.633% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -11699.862% |
| Assertio Holdings, Inc. | 368.58 Million USD | 75.59% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -1428.705% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -405.224% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -325.022% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -327.586% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 45.46% |
| Hempacco Co., Inc. | 7.59 Million USD | -1084.409% |
| Talphera, Inc. | 11.99 Million USD | -650.15% |
| Alvotech | 285.43 Million USD | 68.479% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 36.06% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 73.913% |
| Currenc Group, Inc. | 24 Million USD | -274.855% |
| Kamada Ltd. | 45.42 Million USD | -98.065% |
| Indivior PLC | 911 Million USD | 90.124% |
| Evoke Pharma, Inc. | 12.4 Million USD | -625.025% |
| Flora Growth Corp. | 10.57 Million USD | -750.487% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -327.586% |
| Evolus, Inc. | 189.75 Million USD | 52.586% |
| HUTCHMED (China) Limited | 436.23 Million USD | 79.375% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 41.627% |
| Akanda Corp. | 3.48 Million USD | -2482.827% |